Preview

Merck Business Analysis

Powerful Essays
Open Document
Open Document
1943 Words
Grammar
Grammar
Plagiarism
Plagiarism
Writing
Writing
Score
Score
Merck Business Analysis
Merck: Business Analysis
Merck is a flourishing research-driven pharmaceutical company, which discovers, develops, manufacturers, and promotes an extensive variety of human and animal health products. Although Merck is one of the biggest pharmaceutical companies of the world, they still come across problems today while striving to sustain a lead against its competition. Merck has achieved success with its lengthy history of breakthrough drugs and the development of three significant pharmaceutical products: antibiotics, vitamins, and hormones. Merck’s success relies heavily on its management and how they modify the business model in place to that of the ever-changing economy.
Influence of Economic Trends
The global pharmaceutical market is likely to undergo a wide variety of changes with new competition arising in India, China, Malaysia, South Korea, and Indonesia. This new competition has a growing economy and has made a difference between the product cost and disposable income of consumers. According to NASDAQ (2011),“ Global pharmaceutical market sales are expected to grow at a 4-7% through the year 2013 largely being driven by the growing access to health care in emerging economic regions” (para. 2-5). Short-term growth within this area is stimulated by the United States market, as it continues to be the largest pharmaceutical market in the world. A focal point on research and development in special drugs and generic drugs will remain a strong means to meet 2011 goals of earning $315 billion dollar in sales within the United States.
Strategies
Merck & Co., Inc. has outlined its long-term strategic goals in how the company devises to develop and market medicines and vaccines worldwide. Merck plans to enhance the value of its medicines and vaccines through lifecycle management and will put time into implementing internal and external growth opportunities such as regional business expansion. The company also plans to obtain additional growth from



References: Drug Discovery & Development. (2011). Merck Outlines Long-Term Prospects and Progress on Strategic Plan. Retrieved from http://www.dddmag.com/news-Merck-Outlines-Long-Term-Prospects.aspx Merck & Co., Inc. (2009-2011). Career Choices: Human Resources. Retrieved from http://www.merck.com/careers/explore-careers/career-choices/human-resources.html Merck & Co., Inc. (2009-2011). Employee Diversity. Retrieved from http://www.merck.com/about/how-we-operate/diversity/employee-diversity.html NASDAQ. (2011). Global conditions to influence pharmaceuticals – Industry report featuring OXiGENE and Merck & Co., Inc.. Retrieved from http://www.nasdaq.com/aspx/company-news-story.aspx Scheller, A. (April 2011). Merck chairman discusses corporate responsibility at speaker series. Kogod News. Retrieved from http://www.american.edu/kogod/news/20110324_ksb_richard_clark.cfm Shetty, N. (January 2011). Human Resource Management of Merck and Company [MP GURU]. Message posted to http://www.managementparadise.com/forums/human-resources-management-h-r/214262-human-resource-management-merck-company.html Van Arnum, P. (2008). Merck makes strides in executing a new supply strategy. Pharmaceutical Technology Sourcing and Management, 4(1). Retrieved from http://pharmatech.findpharma.com/pharmtech/Ingredietns+Article/Merck-Makes-Strides-in-Executing-a-New-Supply-Strategy

You May Also Find These Documents Helpful

  • Good Essays

    Merck Case

    • 587 Words
    • 4 Pages

    Merck had a 14% increase in sales between 1997 and 1998 and 22% increase in sales from 1998 – 1999, and a 13% annual increase in earnings over the same period. Merck’s business strategy consists of two parts: (1) developing and marketing new drugs through internal research, and (2) developing partnerships with smaller biotechnology companies. Since 1995, Merck had launched 15 new products that earned $5.9 billion on sales of $32.7 billion. Furthermore, Merck may agree to license new drugs from other firms and with its larger capital and greater assets, can assume the risk of submitting the drug through various regulatory approval phases. If the drug becomes profitable, Merck can earn significant cash flows while paying a royalty to the licensor. However, most important is the option that Merck has in deciding when to abandon or continue on this project (deferability or optionality). If Merck reaches a point when its expected NPV is negative, it can simply abandon the project. As a licensee, Merck can allow smaller biotechnology firms to focus on research and development. These smaller firms often have smaller budgets and are not financially or personnel equipped to handle the costly and long FDA approval process, and the subsequent marketing, distribution, and sales of new drugs. This task is better suited for a larger company, such as Merck, which has more resources and money.…

    • 587 Words
    • 4 Pages
    Good Essays
  • Powerful Essays

    References: 1. Blake, Hannah. “A history of Merck & Co”. Pharmaphorum. May 30, 2013. Retrieved from http://www.pharmaphorum.com/articles/a-history-of-merck-co…

    • 1517 Words
    • 7 Pages
    Powerful Essays
  • Better Essays

    Pharmanet-i3, a subsidiary of inVentive Health, is a world leading clinical research organization committed to the advancement of health around the world. The mission of Pharmanet-i3 is to be a strategic partner to companies that develop therapeutic drugs, and aim to bring drugs to the public that treat disease and improve the quality of life. The company will operate within the industry’s highest quality standards with uncompromising integrity, ethics, and respect for employees, study participants, the environment, and the communities in which the employees live and work. Shareholders can expect superior returns through the implementation of a successful growth strategy (Pharmanet-I3, n.d.).…

    • 1342 Words
    • 6 Pages
    Better Essays
  • Satisfactory Essays

    Drug Companies and Ethics

    • 656 Words
    • 3 Pages

    Merck is one of the largest and most profitable drug companies in the world, but they have also been a leader in a donation program that helps Third World countries in Africa, South America and Yemen since the 1980’s.…

    • 656 Words
    • 3 Pages
    Satisfactory Essays
  • Best Essays

    Ldr 531 Week 5

    • 2421 Words
    • 10 Pages

    Plunkett, J. W. (August 19, 2010). Domestic & Foreign Pharmaceutical Sales, PhRMA Member Companies: 1975-2009. [Electronic version]. Biotechnology, Drugs & Genetics Industry. Retrieved October 24, 2010 from http://www.plunkettresearchonline.com…

    • 2421 Words
    • 10 Pages
    Best Essays
  • Good Essays

    Merck was renowned for its research labs which had decades of achievements, turning out one innovation after another, including drugs for tuberculosis, cholesterol, hypertension, and AIDS. In the early 2000s Merck spent around 3 billion in research; some felt that the company culture was shaped by its research agenda. The company was described as “intense, driven, loyal, scientifically brilliant, collegial, and arrogant”…

    • 2172 Words
    • 7 Pages
    Good Essays
  • Powerful Essays

    Case Merck & Johnson & Johnson are two leaders producers of health care products. Each has considerable assets, and each expends considerable funds each year toward the development of new products. The development of a new health care product is often very expensive, and risky, New products frequently must undergo considerable testing before approval for distribution to the public. For example, it took Johnson & Johnson 4 years and $200 million to develop its 1 Day ACUVUE contact lenses. Below are some basic data complied from the financial statements of these two companies.…

    • 881 Words
    • 4 Pages
    Powerful Essays
  • Good Essays

    Merck's Culture

    • 435 Words
    • 2 Pages

    “May 5, 2005. It was the darkest hour in the pharmaceutical giant 's 114-year history. Merck was drowning in liability suits stemming from Vioxx, its $2.5 billion-a-year arthritis drug, which it had to pull from the market because of a link to heart attacks and strokes. Two other blockbusters worth a combined $7 billion in annual sales were facing patent expirations. And Merck 's labs, which other companies once hailed as a bastion of scientific innovation, were crippled by a culture that buried good ideas under layers of bureaucracy. But in the morass, Clark saw opportunity (www.businessweek.com).”…

    • 435 Words
    • 2 Pages
    Good Essays
  • Powerful Essays

    Merck/Medco Case Analysis

    • 3129 Words
    • 13 Pages

    Medco can also help Merck increase its market share in an industry in which no company has…

    • 3129 Words
    • 13 Pages
    Powerful Essays
  • Powerful Essays

    Merck: Open for Innovation ?

    • 2847 Words
    • 12 Pages

    An analysis of the industry is essential to gain a better insight on how Merck is operating…

    • 2847 Words
    • 12 Pages
    Powerful Essays
  • Best Essays

    The manufacturer like Merck-Medco, Lilly-PCS were concerned about losing access to their industries to PBM. PBMs are companies that administer drug benefit programs for employers and health insurance carriers. Their contracts are directly to managed care organizations, self-insured employers, insurance companies, Medicare, and almost all Federal and State government health benefits plans. To make the benefit plan more affordable PBM lowered their claims processing fees and also offered rebate retention. PBM also processed prescription drug claims, reviewed prescriptions, offered generic and branded medicines through mail services as well. Hence, due to PBM’s efficiency of delivering and processing the drug cut overall cost of health care benefits, the manufacturer industry got a big hit in their business. So, in the early 1990S, a large growth of managed care changed the health care industry that also had a heavy impact on…

    • 2738 Words
    • 11 Pages
    Best Essays
  • Good Essays

    Merck Decision Tree

    • 456 Words
    • 2 Pages

    Merck is a global research-driven pharmaceutical company dedicated to putting patients first. Merck's highest priority areas are Alzheimer’s disease, atherosclerosis, cardiovascular disease, diabetes, novel vaccines, obesity, oncology, pain and sleep disorders. In addition, and importantly for licensing, the following other areas remain of high interest for focused investment in new compounds and mechanisms: antibiotics, antifungals, antivirals (HCV and HIV), asthma, COPD, neurodegeneration, ophthalmology, osteoporosis, schizophrenia, and stroke.…

    • 456 Words
    • 2 Pages
    Good Essays
  • Powerful Essays

    Analysis of the Medicines Company case revealed several critical aspects that need to be addressed. The pharmaceutical industry can be very profitable, but is also very risky. As described in the case, bringing a new drug to market is a costly and lengthy process requiring an average of 10 years. Big Pharmaceutical companies struggle to keep upcoming drugs in their pipeline to provide revenue when existing drugs come off patent and are replaced by generic compounds. With 1 in 4000 compounds making it to market, there is significant risk of failure that can be reduced by having many compounds in development. Additionally, a drug company's reputation can easily be tarnished by safety issues with a compound, dramatically affecting their sales.…

    • 2114 Words
    • 7 Pages
    Powerful Essays
  • Better Essays

    Merck & Co

    • 1066 Words
    • 5 Pages

    Merck had a 14% increase in sales between 1997 and 1998 and 22% increase in sales from 1998 – 1999, and a 13% annual increase in earnings over the same period. Merck’s business strategy consists of two parts: (1) developing and marketing new drugs through internal research, and (2) developing partnerships with smaller biotechnology companies. Since 1995, Merck had launched 15 new products that earned $5.9 billion on sales of $32.7 billion. Furthermore, Merck may agree to license new drugs from other firms and with its larger capital and greater assets, can assume the risk of submitting the drug through various regulatory approval phases. If the drug becomes profitable, Merck can earn significant cash flows while paying a royalty to the licensor. However, most important is the option that Merck has in deciding when to abandon or continue on this project (deferability or optionality). If Merck reaches a point when its expected NPV is negative, it can simply abandon the project.…

    • 1066 Words
    • 5 Pages
    Better Essays
  • Powerful Essays

    Merck and River Blindness

    • 1810 Words
    • 8 Pages

    From a rights/responsibility lens it would appear that Merck has chosen to honor the principles outlined by their founder by adhering to the mission statement. The results lens allows…

    • 1810 Words
    • 8 Pages
    Powerful Essays